pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Pain · news · pharmadog
← back to Pain
News · Pain
146
stories
21d
Opinion: Limb girdle muscular dystrophy patients face a maddening reality
stat
21d
Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial
endpoints
22d
STAT+: FDA expert committee votes in favor of Replimune’s melanoma treatment
stat
22d
Chronically ill people face confusion over new Medicaid work rules and ‘medically frail’ exemption
stat
22d
Convenience Kit Correction: Argon Medical Issues Correction for Convenience Kits Containing Spectra Medical Device Lidocaine Ampules
fda medwatch
22d
NSF testing new Ph.D. model giving trainees academic and industry experience
stat
22d
MapLight CEO on what investors missed in the biotech’s schizophrenia data
biopharma dive
22d
STAT+: Latigo reports mid-stage success for would-be rival to Vertex’s pain drug Journavx
stat
24d
An eye drug biotech banks $118M and stocks its executive suite
biopharma dive
24d
OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer
globenewswire health
24d
After PCOS became PMOS, there’s hope for new awareness among Black and Latina women
stat
24d
MapLight dives despite positive data for schizophrenia drug
biopharma dive
25d
Asia-Pacific Roundup: TGA adopts 23 international scientific guidelines
raps
28d
FDA panel endorses broader use of certain peptides
biopharma dive
28d
This Week at FDA: Diamantas touts onshoring efforts, grants for DHTs, and more
raps
28d
FDA advisory committee backs two more peptides, rejects one for compounding list
raps
29d
FDA panel confronting peptide controversy
stat
29d
Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear
fiercebiotech
29d
Midwest Poultry Services. L.P. Recalls Shell Eggs Due to Possible Salmonella Enteritidis Contamination
fda recalls
Jul 22, 26
Crystalys nets $130M more to push gout drug through late-stage tests
biopharma dive
Jul 22, 26
Celldex ends skin disease program after failing phase 2 test
fiercebiotech
Jul 21, 26
Trump administration says it’s deferring $1B in Medicaid payments to California and Minnesota
stat
Jul 21, 26
The FDA’s 505(b)(2) pathway is an underestimated engine of value creation
biospace
Jul 20, 26
Pain drugmaker Latigo outlines plans to go public
biopharma dive
Jul 20, 26
STAT+: The next step of site-neutral, and a fiery PBM hearing
stat
Jul 20, 26
Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trial
fiercebiotech
Jul 19, 26
Relay Peak Research LLC Recalls Zen Principle® Moringa Capsules Because of Possible Health Risk
fda recalls
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
Jul 18, 26
Opinion: STAT readers on the value of primary care, obesity as a disease, and more
stat
Jul 17, 26
Updated: BlossomHill and Latigo join flourishing IPO queue with cancer, pain drugs
endpoints
← prev
page 3 of 5
next →
